SCM
GBT

Segantii Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Segantii Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-50,000
Closed -$2.63M – 127
2019
Q2 		$2.63M Buy
+50,000
New +$2.87M 0.23% 37

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Segantii Capital Management's GBT Position: Q3 2019 in Review

Segantii Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2019, closing a stake of 50,000 shares — an estimated $2.63M sold.

Segantii Capital Management first reported a position in GBT in Q2 2019 and held it in 1 quarter. The position peaked at $2.63M in Q2 2019. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

  • Segantii Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Segantii Capital Management sold 50,000 Global Blood Therapeutics, Inc. shares in Q3 2019, an estimated $2.63M.
  • Segantii Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 1 quarter.
  • Segantii Capital Management's Global Blood Therapeutics, Inc. position peaked at $2.63M in Q2 2019.
  • 208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Segantii Capital Management's 13F filing for Q3 2019, filed 24 Oct 2019.